JMP Securities Downgrades Synta Pharma. (SNTA) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
Cowen Downgrades Synta Pharma. (SNTA) to Market Perform
October 21, 2015 2:01 PM EDTCowen downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform.
Analyst Boris Peaker commented, "In light of GALAXY-2's stoppage, we are downgrading shares of SNTA from Outperform to Market Perform without a price target. In our view there are limited... More
FBR Capital Downgrades Synta Pharma. (SNTA) to Market Perform Amid GALAXY-2 Termination
October 21, 2015 12:28 PM EDTFBR Capital downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform and cuts its price target from $6 to $2.
Analyst Christopher James noted the following:
No separation of the curves following interim analysis. Following the termination of GALAXY-2, we do not see a clear path forward for ganetespib. Since the remaining studies with ganetespib are... MoreRoth Capital Downgrades Synta Pharma. (SNTA) to Neutral; $1 PT
October 21, 2015 8:41 AM EDTRoth Capital downgraded Synta Pharma. (NASDAQ: SNTA) from Buy to Neutral with a price target of $1.00 (from $13.00).
Analyst Joseph Pantginis commented, "GALAXY-2 has been terminated at the first interim for futility. This is quite disappointing news for ganetespib, and our call for... More
Synta Pharma (SNTA) Terminates Phase 3 GALAXY-2 Trial in Lung Cancer Due to Futility
October 21, 2015 7:25 AM EDTSynta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the studys Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel alone. The IDMC noted... More
